Global Pulmonary Hypertension Drug Market Insights and Forecast to 2028

Global Pulmonary Hypertension Drug Market Insights and Forecast to 2028

Table of Contents
1 Study Coverage
1.1 Pulmonary Hypertension Drug Product Introduction
1.2 Market by Type
1.2.1 Global Pulmonary Hypertension Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 IK-3001
1.2.3 Sildenafil Citrate IMD
1.2.4 IK-7002
1.2.5 Riociguat
1.2.6 SAR-407899
1.2.7 Others
1.3 Market by Application
1.3.1 Global Pulmonary Hypertension Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Pulmonary Hypertension Drug Sales Estimates and Forecasts 2017-2028
2.2 Global Pulmonary Hypertension Drug Revenue Estimates and Forecasts 2017-2028
2.3 Global Pulmonary Hypertension Drug Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Pulmonary Hypertension Drug Sales by Region
2.4.1 Global Pulmonary Hypertension Drug Sales by Region (2017-2022)
2.4.2 Global Sales Pulmonary Hypertension Drug by Region (2023-2028)
2.5 Global Pulmonary Hypertension Drug Revenue by Region
2.5.1 Global Pulmonary Hypertension Drug Revenue by Region (2017-2022)
2.5.2 Global Pulmonary Hypertension Drug Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Pulmonary Hypertension Drug Sales by Manufacturers
3.1.1 Global Top Pulmonary Hypertension Drug Manufacturers by Sales (2017-2022)
3.1.2 Global Pulmonary Hypertension Drug Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Pulmonary Hypertension Drug in 2021
3.2 Global Pulmonary Hypertension Drug Revenue by Manufacturers
3.2.1 Global Pulmonary Hypertension Drug Revenue by Manufacturers (2017-2022)
3.2.2 Global Pulmonary Hypertension Drug Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Pulmonary Hypertension Drug Revenue in 2021
3.3 Global Pulmonary Hypertension Drug Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Pulmonary Hypertension Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Pulmonary Hypertension Drug Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Pulmonary Hypertension Drug Sales by Type
4.1.1 Global Pulmonary Hypertension Drug Historical Sales by Type (2017-2022)
4.1.2 Global Pulmonary Hypertension Drug Forecasted Sales by Type (2023-2028)
4.1.3 Global Pulmonary Hypertension Drug Sales Market Share by Type (2017-2028)
4.2 Global Pulmonary Hypertension Drug Revenue by Type
4.2.1 Global Pulmonary Hypertension Drug Historical Revenue by Type (2017-2022)
4.2.2 Global Pulmonary Hypertension Drug Forecasted Revenue by Type (2023-2028)
4.2.3 Global Pulmonary Hypertension Drug Revenue Market Share by Type (2017-2028)
4.3 Global Pulmonary Hypertension Drug Price by Type
4.3.1 Global Pulmonary Hypertension Drug Price by Type (2017-2022)
4.3.2 Global Pulmonary Hypertension Drug Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Pulmonary Hypertension Drug Sales by Application
5.1.1 Global Pulmonary Hypertension Drug Historical Sales by Application (2017-2022)
5.1.2 Global Pulmonary Hypertension Drug Forecasted Sales by Application (2023-2028)
5.1.3 Global Pulmonary Hypertension Drug Sales Market Share by Application (2017-2028)
5.2 Global Pulmonary Hypertension Drug Revenue by Application
5.2.1 Global Pulmonary Hypertension Drug Historical Revenue by Application (2017-2022)
5.2.2 Global Pulmonary Hypertension Drug Forecasted Revenue by Application (2023-2028)
5.2.3 Global Pulmonary Hypertension Drug Revenue Market Share by Application (2017-2028)
5.3 Global Pulmonary Hypertension Drug Price by Application
5.3.1 Global Pulmonary Hypertension Drug Price by Application (2017-2022)
5.3.2 Global Pulmonary Hypertension Drug Price Forecast by Application (2023-2028)
6 North America
6.1 North America Pulmonary Hypertension Drug Market Size by Type
6.1.1 North America Pulmonary Hypertension Drug Sales by Type (2017-2028)
6.1.2 North America Pulmonary Hypertension Drug Revenue by Type (2017-2028)
6.2 North America Pulmonary Hypertension Drug Market Size by Application
6.2.1 North America Pulmonary Hypertension Drug Sales by Application (2017-2028)
6.2.2 North America Pulmonary Hypertension Drug Revenue by Application (2017-2028)
6.3 North America Pulmonary Hypertension Drug Market Size by Country
6.3.1 North America Pulmonary Hypertension Drug Sales by Country (2017-2028)
6.3.2 North America Pulmonary Hypertension Drug Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Pulmonary Hypertension Drug Market Size by Type
7.1.1 Europe Pulmonary Hypertension Drug Sales by Type (2017-2028)
7.1.2 Europe Pulmonary Hypertension Drug Revenue by Type (2017-2028)
7.2 Europe Pulmonary Hypertension Drug Market Size by Application
7.2.1 Europe Pulmonary Hypertension Drug Sales by Application (2017-2028)
7.2.2 Europe Pulmonary Hypertension Drug Revenue by Application (2017-2028)
7.3 Europe Pulmonary Hypertension Drug Market Size by Country
7.3.1 Europe Pulmonary Hypertension Drug Sales by Country (2017-2028)
7.3.2 Europe Pulmonary Hypertension Drug Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Pulmonary Hypertension Drug Market Size by Type
8.1.1 Asia Pacific Pulmonary Hypertension Drug Sales by Type (2017-2028)
8.1.2 Asia Pacific Pulmonary Hypertension Drug Revenue by Type (2017-2028)
8.2 Asia Pacific Pulmonary Hypertension Drug Market Size by Application
8.2.1 Asia Pacific Pulmonary Hypertension Drug Sales by Application (2017-2028)
8.2.2 Asia Pacific Pulmonary Hypertension Drug Revenue by Application (2017-2028)
8.3 Asia Pacific Pulmonary Hypertension Drug Market Size by Region
8.3.1 Asia Pacific Pulmonary Hypertension Drug Sales by Region (2017-2028)
8.3.2 Asia Pacific Pulmonary Hypertension Drug Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Pulmonary Hypertension Drug Market Size by Type
9.1.1 Latin America Pulmonary Hypertension Drug Sales by Type (2017-2028)
9.1.2 Latin America Pulmonary Hypertension Drug Revenue by Type (2017-2028)
9.2 Latin America Pulmonary Hypertension Drug Market Size by Application
9.2.1 Latin America Pulmonary Hypertension Drug Sales by Application (2017-2028)
9.2.2 Latin America Pulmonary Hypertension Drug Revenue by Application (2017-2028)
9.3 Latin America Pulmonary Hypertension Drug Market Size by Country
9.3.1 Latin America Pulmonary Hypertension Drug Sales by Country (2017-2028)
9.3.2 Latin America Pulmonary Hypertension Drug Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Pulmonary Hypertension Drug Market Size by Type
10.1.1 Middle East and Africa Pulmonary Hypertension Drug Sales by Type (2017-2028)
10.1.2 Middle East and Africa Pulmonary Hypertension Drug Revenue by Type (2017-2028)
10.2 Middle East and Africa Pulmonary Hypertension Drug Market Size by Application
10.2.1 Middle East and Africa Pulmonary Hypertension Drug Sales by Application (2017-2028)
10.2.2 Middle East and Africa Pulmonary Hypertension Drug Revenue by Application (2017-2028)
10.3 Middle East and Africa Pulmonary Hypertension Drug Market Size by Country
10.3.1 Middle East and Africa Pulmonary Hypertension Drug Sales by Country (2017-2028)
10.3.2 Middle East and Africa Pulmonary Hypertension Drug Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Sanofi
11.1.1 Sanofi Corporation Information
11.1.2 Sanofi Overview
11.1.3 Sanofi Pulmonary Hypertension Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Sanofi Pulmonary Hypertension Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Sanofi Recent Developments
11.2 Vectura Group plc
11.2.1 Vectura Group plc Corporation Information
11.2.2 Vectura Group plc Overview
11.2.3 Vectura Group plc Pulmonary Hypertension Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Vectura Group plc Pulmonary Hypertension Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Vectura Group plc Recent Developments
11.3 Bayer AG
11.3.1 Bayer AG Corporation Information
11.3.2 Bayer AG Overview
11.3.3 Bayer AG Pulmonary Hypertension Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Bayer AG Pulmonary Hypertension Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Bayer AG Recent Developments
11.4 Ikaria Inc.
11.4.1 Ikaria Inc. Corporation Information
11.4.2 Ikaria Inc. Overview
11.4.3 Ikaria Inc. Pulmonary Hypertension Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Ikaria Inc. Pulmonary Hypertension Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Ikaria Inc. Recent Developments
11.5 Proreo Pharma AG
11.5.1 Proreo Pharma AG Corporation Information
11.5.2 Proreo Pharma AG Overview
11.5.3 Proreo Pharma AG Pulmonary Hypertension Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Proreo Pharma AG Pulmonary Hypertension Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Proreo Pharma AG Recent Developments
11.6 Vicore Pharma AB
11.6.1 Vicore Pharma AB Corporation Information
11.6.2 Vicore Pharma AB Overview
11.6.3 Vicore Pharma AB Pulmonary Hypertension Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Vicore Pharma AB Pulmonary Hypertension Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Vicore Pharma AB Recent Developments
11.7 Biolab Sanus Farmaceutica Ltda.
11.7.1 Biolab Sanus Farmaceutica Ltda. Corporation Information
11.7.2 Biolab Sanus Farmaceutica Ltda. Overview
11.7.3 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Biolab Sanus Farmaceutica Ltda. Recent Developments
11.8 Hanmi Pharmaceuticals, Co. Ltd.
11.8.1 Hanmi Pharmaceuticals, Co. Ltd. Corporation Information
11.8.2 Hanmi Pharmaceuticals, Co. Ltd. Overview
11.8.3 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Hanmi Pharmaceuticals, Co. Ltd. Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Pulmonary Hypertension Drug Industry Chain Analysis
12.2 Pulmonary Hypertension Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Pulmonary Hypertension Drug Production Mode & Process
12.4 Pulmonary Hypertension Drug Sales and Marketing
12.4.1 Pulmonary Hypertension Drug Sales Channels
12.4.2 Pulmonary Hypertension Drug Distributors
12.5 Pulmonary Hypertension Drug Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Pulmonary Hypertension Drug Industry Trends
13.2 Pulmonary Hypertension Drug Market Drivers
13.3 Pulmonary Hypertension Drug Market Challenges
13.4 Pulmonary Hypertension Drug Market Restraints
14 Key Findings in The Global Pulmonary Hypertension Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Pulmonary Hypertension Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of IK-3001
Table 3. Major Manufacturers of Sildenafil Citrate IMD
Table 4. Major Manufacturers of IK-7002
Table 5. Major Manufacturers of Riociguat
Table 6. Major Manufacturers of SAR-407899
Table 7. Major Manufacturers of Others
Table 8. Global Pulmonary Hypertension Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 9. Global Pulmonary Hypertension Drug Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 10. Global Pulmonary Hypertension Drug Sales by Region (2017-2022) & (K Pcs)
Table 11. Global Pulmonary Hypertension Drug Sales Market Share by Region (2017-2022)
Table 12. Global Pulmonary Hypertension Drug Sales by Region (2023-2028) & (K Pcs)
Table 13. Global Pulmonary Hypertension Drug Sales Market Share by Region (2023-2028)
Table 14. Global Pulmonary Hypertension Drug Revenue by Region (2017-2022) & (US$ Million)
Table 15. Global Pulmonary Hypertension Drug Revenue Market Share by Region (2017-2022)
Table 16. Global Pulmonary Hypertension Drug Revenue by Region (2023-2028) & (US$ Million)
Table 17. Global Pulmonary Hypertension Drug Revenue Market Share by Region (2023-2028)
Table 18. Global Pulmonary Hypertension Drug Sales by Manufacturers (2017-2022) & (K Pcs)
Table 19. Global Pulmonary Hypertension Drug Sales Share by Manufacturers (2017-2022)
Table 20. Global Pulmonary Hypertension Drug Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 21. Global Pulmonary Hypertension Drug Revenue Share by Manufacturers (2017-2022)
Table 22. Pulmonary Hypertension Drug Price by Manufacturers (2017-2022) &(USD/Pcs)
Table 23. Global Pulmonary Hypertension Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Pulmonary Hypertension Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Hypertension Drug as of 2021)
Table 25. Pulmonary Hypertension Drug Manufacturing Base Distribution and Headquarters
Table 26. Manufacturers Pulmonary Hypertension Drug Product Offered
Table 27. Date of Manufacturers Enter into Pulmonary Hypertension Drug Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Pulmonary Hypertension Drug Sales by Type (2017-2022) & (K Pcs)
Table 30. Global Pulmonary Hypertension Drug Sales by Type (2023-2028) & (K Pcs)
Table 31. Global Pulmonary Hypertension Drug Sales Share by Type (2017-2022)
Table 32. Global Pulmonary Hypertension Drug Sales Share by Type (2023-2028)
Table 33. Global Pulmonary Hypertension Drug Revenue by Type (2017-2022) & (US$ Million)
Table 34. Global Pulmonary Hypertension Drug Revenue by Type (2023-2028) & (US$ Million)
Table 35. Global Pulmonary Hypertension Drug Revenue Share by Type (2017-2022)
Table 36. Global Pulmonary Hypertension Drug Revenue Share by Type (2023-2028)
Table 37. Pulmonary Hypertension Drug Price by Type (2017-2022) & (USD/Pcs)
Table 38. Global Pulmonary Hypertension Drug Price Forecast by Type (2023-2028) & (USD/Pcs)
Table 39. Global Pulmonary Hypertension Drug Sales by Application (2017-2022) & (K Pcs)
Table 40. Global Pulmonary Hypertension Drug Sales by Application (2023-2028) & (K Pcs)
Table 41. Global Pulmonary Hypertension Drug Sales Share by Application (2017-2022)
Table 42. Global Pulmonary Hypertension Drug Sales Share by Application (2023-2028)
Table 43. Global Pulmonary Hypertension Drug Revenue by Application (2017-2022) & (US$ Million)
Table 44. Global Pulmonary Hypertension Drug Revenue by Application (2023-2028) & (US$ Million)
Table 45. Global Pulmonary Hypertension Drug Revenue Share by Application (2017-2022)
Table 46. Global Pulmonary Hypertension Drug Revenue Share by Application (2023-2028)
Table 47. Pulmonary Hypertension Drug Price by Application (2017-2022) & (USD/Pcs)
Table 48. Global Pulmonary Hypertension Drug Price Forecast by Application (2023-2028) & (USD/Pcs)
Table 49. North America Pulmonary Hypertension Drug Sales by Type (2017-2022) & (K Pcs)
Table 50. North America Pulmonary Hypertension Drug Sales by Type (2023-2028) & (K Pcs)
Table 51. North America Pulmonary Hypertension Drug Revenue by Type (2017-2022) & (US$ Million)
Table 52. North America Pulmonary Hypertension Drug Revenue by Type (2023-2028) & (US$ Million)
Table 53. North America Pulmonary Hypertension Drug Sales by Application (2017-2022) & (K Pcs)
Table 54. North America Pulmonary Hypertension Drug Sales by Application (2023-2028) & (K Pcs)
Table 55. North America Pulmonary Hypertension Drug Revenue by Application (2017-2022) & (US$ Million)
Table 56. North America Pulmonary Hypertension Drug Revenue by Application (2023-2028) & (US$ Million)
Table 57. North America Pulmonary Hypertension Drug Sales by Country (2017-2022) & (K Pcs)
Table 58. North America Pulmonary Hypertension Drug Sales by Country (2023-2028) & (K Pcs)
Table 59. North America Pulmonary Hypertension Drug Revenue by Country (2017-2022) & (US$ Million)
Table 60. North America Pulmonary Hypertension Drug Revenue by Country (2023-2028) & (US$ Million)
Table 61. Europe Pulmonary Hypertension Drug Sales by Type (2017-2022) & (K Pcs)
Table 62. Europe Pulmonary Hypertension Drug Sales by Type (2023-2028) & (K Pcs)
Table 63. Europe Pulmonary Hypertension Drug Revenue by Type (2017-2022) & (US$ Million)
Table 64. Europe Pulmonary Hypertension Drug Revenue by Type (2023-2028) & (US$ Million)
Table 65. Europe Pulmonary Hypertension Drug Sales by Application (2017-2022) & (K Pcs)
Table 66. Europe Pulmonary Hypertension Drug Sales by Application (2023-2028) & (K Pcs)
Table 67. Europe Pulmonary Hypertension Drug Revenue by Application (2017-2022) & (US$ Million)
Table 68. Europe Pulmonary Hypertension Drug Revenue by Application (2023-2028) & (US$ Million)
Table 69. Europe Pulmonary Hypertension Drug Sales by Country (2017-2022) & (K Pcs)
Table 70. Europe Pulmonary Hypertension Drug Sales by Country (2023-2028) & (K Pcs)
Table 71. Europe Pulmonary Hypertension Drug Revenue by Country (2017-2022) & (US$ Million)
Table 72. Europe Pulmonary Hypertension Drug Revenue by Country (2023-2028) & (US$ Million)
Table 73. Asia Pacific Pulmonary Hypertension Drug Sales by Type (2017-2022) & (K Pcs)
Table 74. Asia Pacific Pulmonary Hypertension Drug Sales by Type (2023-2028) & (K Pcs)
Table 75. Asia Pacific Pulmonary Hypertension Drug Revenue by Type (2017-2022) & (US$ Million)
Table 76. Asia Pacific Pulmonary Hypertension Drug Revenue by Type (2023-2028) & (US$ Million)
Table 77. Asia Pacific Pulmonary Hypertension Drug Sales by Application (2017-2022) & (K Pcs)
Table 78. Asia Pacific Pulmonary Hypertension Drug Sales by Application (2023-2028) & (K Pcs)
Table 79. Asia Pacific Pulmonary Hypertension Drug Revenue by Application (2017-2022) & (US$ Million)
Table 80. Asia Pacific Pulmonary Hypertension Drug Revenue by Application (2023-2028) & (US$ Million)
Table 81. Asia Pacific Pulmonary Hypertension Drug Sales by Region (2017-2022) & (K Pcs)
Table 82. Asia Pacific Pulmonary Hypertension Drug Sales by Region (2023-2028) & (K Pcs)
Table 83. Asia Pacific Pulmonary Hypertension Drug Revenue by Region (2017-2022) & (US$ Million)
Table 84. Asia Pacific Pulmonary Hypertension Drug Revenue by Region (2023-2028) & (US$ Million)
Table 85. Latin America Pulmonary Hypertension Drug Sales by Type (2017-2022) & (K Pcs)
Table 86. Latin America Pulmonary Hypertension Drug Sales by Type (2023-2028) & (K Pcs)
Table 87. Latin America Pulmonary Hypertension Drug Revenue by Type (2017-2022) & (US$ Million)
Table 88. Latin America Pulmonary Hypertension Drug Revenue by Type (2023-2028) & (US$ Million)
Table 89. Latin America Pulmonary Hypertension Drug Sales by Application (2017-2022) & (K Pcs)
Table 90. Latin America Pulmonary Hypertension Drug Sales by Application (2023-2028) & (K Pcs)
Table 91. Latin America Pulmonary Hypertension Drug Revenue by Application (2017-2022) & (US$ Million)
Table 92. Latin America Pulmonary Hypertension Drug Revenue by Application (2023-2028) & (US$ Million)
Table 93. Latin America Pulmonary Hypertension Drug Sales by Country (2017-2022) & (K Pcs)
Table 94. Latin America Pulmonary Hypertension Drug Sales by Country (2023-2028) & (K Pcs)
Table 95. Latin America Pulmonary Hypertension Drug Revenue by Country (2017-2022) & (US$ Million)
Table 96. Latin America Pulmonary Hypertension Drug Revenue by Country (2023-2028) & (US$ Million)
Table 97. Middle East and Africa Pulmonary Hypertension Drug Sales by Type (2017-2022) & (K Pcs)
Table 98. Middle East and Africa Pulmonary Hypertension Drug Sales by Type (2023-2028) & (K Pcs)
Table 99. Middle East and Africa Pulmonary Hypertension Drug Revenue by Type (2017-2022) & (US$ Million)
Table 100. Middle East and Africa Pulmonary Hypertension Drug Revenue by Type (2023-2028) & (US$ Million)
Table 101. Middle East and Africa Pulmonary Hypertension Drug Sales by Application (2017-2022) & (K Pcs)
Table 102. Middle East and Africa Pulmonary Hypertension Drug Sales by Application (2023-2028) & (K Pcs)
Table 103. Middle East and Africa Pulmonary Hypertension Drug Revenue by Application (2017-2022) & (US$ Million)
Table 104. Middle East and Africa Pulmonary Hypertension Drug Revenue by Application (2023-2028) & (US$ Million)
Table 105. Middle East and Africa Pulmonary Hypertension Drug Sales by Country (2017-2022) & (K Pcs)
Table 106. Middle East and Africa Pulmonary Hypertension Drug Sales by Country (2023-2028) & (K Pcs)
Table 107. Middle East and Africa Pulmonary Hypertension Drug Revenue by Country (2017-2022) & (US$ Million)
Table 108. Middle East and Africa Pulmonary Hypertension Drug Revenue by Country (2023-2028) & (US$ Million)
Table 109. Sanofi Corporation Information
Table 110. Sanofi Description and Major Businesses
Table 111. Sanofi Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 112. Sanofi Pulmonary Hypertension Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 113. Sanofi Recent Developments
Table 114. Vectura Group plc Corporation Information
Table 115. Vectura Group plc Description and Major Businesses
Table 116. Vectura Group plc Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 117. Vectura Group plc Pulmonary Hypertension Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 118. Vectura Group plc Recent Developments
Table 119. Bayer AG Corporation Information
Table 120. Bayer AG Description and Major Businesses
Table 121. Bayer AG Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 122. Bayer AG Pulmonary Hypertension Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 123. Bayer AG Recent Developments
Table 124. Ikaria Inc. Corporation Information
Table 125. Ikaria Inc. Description and Major Businesses
Table 126. Ikaria Inc. Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 127. Ikaria Inc. Pulmonary Hypertension Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 128. Ikaria Inc. Recent Developments
Table 129. Proreo Pharma AG Corporation Information
Table 130. Proreo Pharma AG Description and Major Businesses
Table 131. Proreo Pharma AG Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 132. Proreo Pharma AG Pulmonary Hypertension Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 133. Proreo Pharma AG Recent Developments
Table 134. Vicore Pharma AB Corporation Information
Table 135. Vicore Pharma AB Description and Major Businesses
Table 136. Vicore Pharma AB Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 137. Vicore Pharma AB Pulmonary Hypertension Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 138. Vicore Pharma AB Recent Developments
Table 139. Biolab Sanus Farmaceutica Ltda. Corporation Information
Table 140. Biolab Sanus Farmaceutica Ltda. Description and Major Businesses
Table 141. Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 142. Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 143. Biolab Sanus Farmaceutica Ltda. Recent Developments
Table 144. Hanmi Pharmaceuticals, Co. Ltd. Corporation Information
Table 145. Hanmi Pharmaceuticals, Co. Ltd. Description and Major Businesses
Table 146. Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 147. Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 148. Hanmi Pharmaceuticals, Co. Ltd. Recent Developments
Table 149. Key Raw Materials Lists
Table 150. Raw Materials Key Suppliers Lists
Table 151. Pulmonary Hypertension Drug Distributors List
Table 152. Pulmonary Hypertension Drug Customers List
Table 153. Pulmonary Hypertension Drug Market Trends
Table 154. Pulmonary Hypertension Drug Market Drivers
Table 155. Pulmonary Hypertension Drug Market Challenges
Table 156. Pulmonary Hypertension Drug Market Restraints
Table 157. Research Programs/Design for This Report
Table 158. Key Data Information from Secondary Sources
Table 159. Key Data Information from Primary Sources
List of Figures
Figure 1. Pulmonary Hypertension Drug Product Picture
Figure 3. Global Pulmonary Hypertension Drug Market Share by Type in 2021 & 2028
Figure 3. IK-3001 Product Picture
Figure 4. Sildenafil Citrate IMD Product Picture
Figure 5. IK-7002 Product Picture
Figure 6. Riociguat Product Picture
Figure 7. SAR-407899 Product Picture
Figure 8. Others Product Picture
Figure 9. Global Pulmonary Hypertension Drug Market Share by Application in 2021 & 2028
Figure 10. Clinic
Figure 11. Hospital
Figure 12. Others
Figure 13. Pulmonary Hypertension Drug Report Years Considered
Figure 14. Global Pulmonary Hypertension Drug Sales 2017-2028 (K Pcs)
Figure 15. Global Pulmonary Hypertension Drug Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 16. Global Pulmonary Hypertension Drug Revenue 2017-2028 (US$ Million)
Figure 17. Global Pulmonary Hypertension Drug Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 18. Global Pulmonary Hypertension Drug Sales Market Share by Region (2017-2022)
Figure 19. Global Pulmonary Hypertension Drug Sales Market Share by Region (2023-2028)
Figure 20. North America Pulmonary Hypertension Drug Sales YoY (2017-2028) & (K Pcs)
Figure 21. North America Pulmonary Hypertension Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 22. Europe Pulmonary Hypertension Drug Sales YoY (2017-2028) & (K Pcs)
Figure 23. Europe Pulmonary Hypertension Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 24. Asia-Pacific Pulmonary Hypertension Drug Sales YoY (2017-2028) & (K Pcs)
Figure 25. Asia-Pacific Pulmonary Hypertension Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 26. Latin America Pulmonary Hypertension Drug Sales YoY (2017-2028) & (K Pcs)
Figure 27. Latin America Pulmonary Hypertension Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 28. Middle East & Africa Pulmonary Hypertension Drug Sales YoY (2017-2028) & (K Pcs)
Figure 29. Middle East & Africa Pulmonary Hypertension Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 30. The Pulmonary Hypertension Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 31. The Top 5 and 10 Largest Manufacturers of Pulmonary Hypertension Drug in the World: Market Share by Pulmonary Hypertension Drug Revenue in 2021
Figure 32. Global Pulmonary Hypertension Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 33. Global Pulmonary Hypertension Drug Sales Market Share by Type (2017-2028)
Figure 34. Global Pulmonary Hypertension Drug Revenue Market Share by Type (2017-2028)
Figure 35. Global Pulmonary Hypertension Drug Sales Market Share by Application (2017-2028)
Figure 36. Global Pulmonary Hypertension Drug Revenue Market Share by Application (2017-2028)
Figure 37. North America Pulmonary Hypertension Drug Sales Market Share by Type (2017-2028)
Figure 38. North America Pulmonary Hypertension Drug Revenue Market Share by Type (2017-2028)
Figure 39. North America Pulmonary Hypertension Drug Sales Market Share by Application (2017-2028)
Figure 40. North America Pulmonary Hypertension Drug Revenue Market Share by Application (2017-2028)
Figure 41. North America Pulmonary Hypertension Drug Sales Share by Country (2017-2028)
Figure 42. North America Pulmonary Hypertension Drug Revenue Share by Country (2017-2028)
Figure 43. U.S. Pulmonary Hypertension Drug Revenue (2017-2028) & (US$ Million)
Figure 44. Canada Pulmonary Hypertension Drug Revenue (2017-2028) & (US$ Million)
Figure 45. Europe Pulmonary Hypertension Drug Sales Market Share by Type (2017-2028)
Figure 46. Europe Pulmonary Hypertension Drug Revenue Market Share by Type (2017-2028)
Figure 47. Europe Pulmonary Hypertension Drug Sales Market Share by Application (2017-2028)
Figure 48. Europe Pulmonary Hypertension Drug Revenue Market Share by Application (2017-2028)
Figure 49. Europe Pulmonary Hypertension Drug Sales Share by Country (2017-2028)
Figure 50. Europe Pulmonary Hypertension Drug Revenue Share by Country (2017-2028)
Figure 51. Germany Pulmonary Hypertension Drug Revenue (2017-2028) & (US$ Million)
Figure 52. France Pulmonary Hypertension Drug Revenue (2017-2028) & (US$ Million)
Figure 53. U.K. Pulmonary Hypertension Drug Revenue (2017-2028) & (US$ Million)
Figure 54. Italy Pulmonary Hypertension Drug Revenue (2017-2028) & (US$ Million)
Figure 55. Russia Pulmonary Hypertension Drug Revenue (2017-2028) & (US$ Million)
Figure 56. Asia Pacific Pulmonary Hypertension Drug Sales Market Share by Type (2017-2028)
Figure 57. Asia Pacific Pulmonary Hypertension Drug Revenue Market Share by Type (2017-2028)
Figure 58. Asia Pacific Pulmonary Hypertension Drug Sales M

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Antioxidant Vitamins Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100

The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......

Global Clavulanate Potassium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......

Global Amoxicillin Sodium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84

The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......

Global Melatonin Supplements Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......

Global Sleeping Pills (Prescription Drugs) Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93

The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......

Global Sleeping Pills Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94

The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Zinc Oral Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......

Global Zinc Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......

Global Anti-Infectives Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78

The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs